Diabetes does not alter low-affinity, high-capacity proteoglycan binding sites for lipoprotein lipase on the endothelium of perfused hearts.
Answers are grounded in this paper and cite their sources.
Preserved endothelial LPL binding in diabetic rat hearts; leaves open mechanisms of reduced activity and relevance to human diabetic cardiomyopathy.
The possibility that diabetes reduces functional, heparin-releasable lipoprotein lipase (HR-LPL) activity on the coronary vasculature of perfused hearts by altering endothelial binding sites for the enzyme was examined by measuring the binding and subsequent heparin-induced release of exogenous lipoprotein lipase purified from bovine milk (mLPL). Rat hearts were first perfused with heparin (5 U/mL) for 5 min to displace endogenous HR-LPL into the perfusate. The subsequent perfusion of control hearts with 0.05-2 micrograms/mL mLPL resulted in a progressive increase in bound exogenous enzyme that could be released by a second heparin perfusion. Induction of an acute, insulin-deficient model of diabetes (100 mg/kg streptozotocin 4-5 days prior to heart perfusions) reduced endogenous HR-LPL activity, but the binding and heparin-induced release of mLPL (0.5 microgram/mL) were the same as measured in control hearts. Therefore, diabetes does not alter low-affinity, high-capacity proteoglycan binding sites for mLPL on the endothelium of perfused hearts.
No takes yet. Share an insight, caveat, or question.
Liu et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: